Tiamulin

Respiratory tract and mycoplasma infections in livestock and poultry are high-incidence diseases in the global livestock breeding sector, and the industry has long been plagued by the problems of easy development of drug resistance and high treatment costs. Tiamulin is a pleuromutilin class of antibiotic exclusively for animals. It binds to the 50S subunit of bacterial ribosomes, inhibits the activity of peptidyl transferase and thus blocks protein synthesis. It is highly sensitive to various pathogenic bacteria in livestock and poultry such as Mycoplasma hyopneumoniae, Actinobacillus pleuropneumoniae and Mycoplasma gallisepticum. It is mainly used clinically for the prevention and treatment of swine enzootic pneumonia, porcine actinobacillus pleuropneumonia and chronic respiratory disease in chickens, and is one of the core drugs in the prevention and control system for respiratory diseases in livestock and poultry.

The global tiamulin market size was approximately USD 210 million in 2023, with a compound annual growth rate of 4.8% from 2019 to 2023. The growth momentum mainly comes from the expansion of the global intensive breeding scale and the continuous increase in animal health investment. The competitive landscape features a significant concentration of production capacity, with China and the European Union being the core production regions. Among them, China's API production capacity accounts for about 62% of the total global supply, and leading enterprises occupy the major share of the export market by virtue of their advantages in fermentation processes. With the advancement of policies on reducing and restricting the use of antibiotics at the breeding end, there is still room for further increase in the market demand for tiamulin with low residue and high sensitivity.

The original developer of tiamulin is Sandoz AG of Switzerland, with the original brand name "Thiamulin". The core compound patent expired globally in 1999. At present, the mainstream dosage forms include soluble powder, premix and injection, and common specifications cover 10% soluble powder, 80% premix, 10% injection, etc. Its original preparation has been listed as a reference listed drug by the FDA. Multiple approval numbers for tiamulin preparations have been issued in China. In terms of APIs, a number of enterprises have obtained A-status registration numbers from CDE, which can be legally associated with preparation declarations. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO provides a full set of impurity reference standards for tiamulin API, and most products are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. Meanwhile, the products meet the compliance requirements of multiple regulations such as Chinese Pharmacopoeia and FDA, and fully meet the full-process needs of enterprises in drug research and development, quality research and production quality control.